One Prediction For US FDA Under Biden: More Advisory Committees

 
• By Michael McCaughan

The US FDA was extraordinarily selective in its use of advisory committees for new drug applications in 2020. It is safe to bet that trend will change under President Elect Biden’s team.

Rostrum with microphone and computer in conference hall
Could the US FDA return to in-person advisory committees this year?

More from US FDA Performance Tracker

More from Regulatory Trackers